Biocorrx (OTCMKTS:BICX) Posts Earnings Results, Misses Expectations By $0.05 EPS

Biocorrx (OTCMKTS:BICX) posted its earnings results on Friday. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05), Zacks reports. The firm had revenue of $0.63 million for the quarter, compared to analyst estimates of $0.19 million.

Biocorrx Trading Up 3.2%

OTCMKTS BICX traded up $0.01 on Friday, reaching $0.45. The stock had a trading volume of 2,003 shares, compared to its average volume of 629. The company has a market capitalization of $9.07 million, a price-to-earnings ratio of -1.28 and a beta of 0.07. The business has a 50 day moving average price of $0.40 and a 200 day moving average price of $0.37. Biocorrx has a 1 year low of $0.20 and a 1 year high of $1.45.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Biocorrx to a “hold” rating in a research report on Tuesday, September 2nd. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has an average rating of “Hold”.

About Biocorrx

BioCorRx Inc, through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition.